Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 23, 2026

The 1 Tech Stock I Keep Adding To on Red Days -- and Why I'll Do It Again

View original at nasdaq.com
The 1 Tech Stock I Keep Adding To on Red Days -- and Why I'll Do It Again Key Points Netlist owns patents that form the foundation of memory chips, resulting in legal wins against Micron and Samsung that can produce meaningful licensing royalties in the future…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Netlist remains well positioned to capitalize on AI memory technologies — DDR5 and HBM — through our products and IP assets.

    60% confidence
  • Netlist can issue an injunction that bans the sale of memory chips in the U.S., ruining backlogs in the process.

    60% confidence
  • Netlist has silently become a major part of the AI bottleneck due to its patents.

    60% confidence
  • The jury verdicts from Micron and Samsung alone are worth almost Netlist's entire market cap.

    60% confidence
  • The longer Micron and Samsung drag their feet in the patent cases, the more consequential the damages may become.

    60% confidence
  • If Netlist continues to deliver high sequential growth and scores big legal wins resulting in licensing royalties, its stock should soar.

    60% confidence
  • Motley Fool Stock Advisor's total average return is 993%, compared to 208% for the S&P 500.

    60% confidence
  • Netlist gets far more negotiating power as the AI boom continues, which can result in better licensing terms.

    60% confidence
  • Netlist was not among the Motley Fool Stock Advisor's 10 best stocks for investors to buy now as of May 22, 2026.

    60% confidence
  • Consecutive quarters of high sequential growth can be an indicator of a breakout AI stock, following the pattern of Sandisk and Micron which delivered multiple quarters of high sequential growth before most investors noticed the opportunity.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
The 1 Tech Stock I Keep Adding To on Red Days -- and Why I'll Do It Again — Source | Via News | ViaNews Market